Intellia Therapeutics, Inc. reported an insider ownership change involving Michael P. Dube in a Form 4 filed on July 6, 2026, covering a transaction dated July 1, 2026. The filing relates to Intellia common stock and reports the sale of 2,641 shares at a reported weighted-average price of $16.78 per share. The transaction was reported under transaction code “S,” indicating a sale, but the filing explains that it was not a discretionary open-market trade by Dube. Instead, the sale was a mandatory “sell-to-cover” transaction used to satisfy tax withholding obligations triggered by the vesting of restricted stock units, or RSUs, on July 1, 2026. According to the explanatory notes, the reported $16.78 price was a weighted-average price. The shares were sold in multiple transactions at prices ranging from $16.78 to $17.12 per share, inclusive. The filing states that Dube will provide detailed price-by-price transaction information upon request by SEC staff, Intellia, or a company security holder. The document does not provide a post-transaction beneficial ownership total in the text supplied. The filing was signed on Dube’s behalf by James Basta, attorney-in-fact, on July 6, 2026.
Stock detail
Intellia Therapeutics (NTLA) stock price, chart, and key data
View Intellia Therapeutics stock price, chart movement, and headline metrics on Woodstock's stock detail page.
Stock detail
Intellia Therapeutics
NTLA · XNAS
+$5.46 (+48.71%) past day
$16.67
Overnight $16.63 (-0.24%)
Key metrics
Financials
Quarterly revenue, profitability, and balance-sheet snapshot
Operating income & Operating cash flow
Quarterly revenue, profitability, and balance-sheet snapshot
Total assets & Total liabilities
Quarterly revenue, profitability, and balance-sheet snapshot
Total equity & Shares outstanding
Quarterly revenue, profitability, and balance-sheet snapshot
Day range
$10.73 - $11.43
52-week range
$7.95 - $28.24
Close price
$11.10
Market cap
$1.6B
P/E ratio
-20.58
Beta
1.77
Financials
FY2026 Q1Operating income
-$101M
Operating cash flow
-$117M
EPS
—
Shares outstanding
139.7M
Total assets
$759M
Total equity
$621M
Total liabilities
$138M
About the company
Intellia Therapeutics Inc
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.
Analyst rating summary
A current read on analyst sentiment from the insight feed.
Mean target
$20.65
8
Buy
/ 19
Recent calls
07/15/2026
Wolfe Research
Andy Chen
Sell · Price target $9.00
07/10/2026
Wedbush
Unknown Analyst
Hold · Price target $17.00
06/16/2026
Canaccord Genuity
Whitney Ijem
Buy · Price target $49.00
Ticker holders
Review politician disclosures and insider transactions in tabs.
Holder directory
Select a heading to reorder by name, activity date, buy/sell, or displayed value.
#1Don Beyer
democrat · House · VA-8
- Sell$15,001 / $32,501 / $50,000
- Sell$15,001 / $32,501 / $50,000
- Sell$1,000 / $8,000 / $15,000
- Sell$1,000 / $8,000 / $15,000
- Sell$1,000 / $8,000 / $15,000
- Sell$1,001 / $8,001 / $15,000
#2Tom Carper
democrat · Senate · DE
- Sell$1,000 / $8,000 / $15,000
- Sell$1,000 / $8,000 / $15,000
- Buy$1,000 / $8,000 / $15,000
- Buy$1,000 / $8,000 / $15,000
Market action
A concise summary of the latest filing, transaction, or market-moving item.
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app